|
|
4/01/22
|
Neurocrine Biosciences Inc, a neuroscience-focused, biopharmaceutical company, has signed a lease at for 535k sf of Class A life science and office space at Aperture Del Mar in San Diego’s Del Mar Heights area, in one of the largest leases in San Diego history. The lease includes four buildings on 15.72 acres at the new coastal campus, on Edgewood Bend Court.
Neurocrine, one of San Diego’s largest life sciences companies, will relocate its headquarters from 12780 El Camino Real, and begin to move into the new campus in 2023. Terms of the deal were not immediately disclosed.
The campus is owned by Gemdale USA Corporation, who acquired the property from Lincoln Property Company in October 2019 with development beginning a month later. Phase 1 of Aperture Del Mar, including the parking structure, was completed in November 2021. Neurocrine Biosciences will occupy four office and research buildings totaling 535k sf and has the option to expand into a fifth building which can offer up to another 125k sf.
Phase 1 of the campus was designed by the world’s largest architecture firm, Gensler, offering a culmination of multiple architectural styles that features superior connectivity between each building and floor, as well as the outdoor environment. It was designed to streamline routines, eliminate distractions, and stimulate the creative thinking that sparks breakthroughs. Multiple balconies, pocket doors and exterior stairwells create collision points in a central promenade to curate the ultimate user experience.
Additionally, each building features 15-foot clear height, open and flexible floorplates and floor-to-ceiling glass that creates abundant natural light and panoramic views. This unique setting, featuring unobstructed view corridors, is centered around programmed gathering areas, on-site and off-site amenities, trails and parks for today’s workforce. The outdoor spaces blend seamlessly with the indoor spaces and feature a boutique coffee roaster, event lawn, sports courts, walking paths, dog park, amphitheater, fitness areas and gym with spa-like showers and lockers.
For three decades, Neurocrine Biosciences, one of San Diego’s largest life sciences companies, has applied its unique insights into neuroscience to advance medicines for neurological, neuroendocrine, and neuropsychiatric disorders. It has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.
JLL’s team of Chad Urie and Grant Schoneman represented Neurocrine Biosciences in the deal. Gemdale USA was repped by JLL’s Tony Russell.
"Long before our lease with Neurocrine Biosciences, we had a vision to go spec for Phase 1 of this property, believing in the strength of this market,” said Josh Goldman, Managing Director, Development at Gemdale USA Corporation. “Neurocrine Biosciences is the perfect tenant for Aperture Del Mar with its history in San Diego and continued growth in the biopharmaceutical industry.”
|
|
 Return to the Archive page
|
|
|
|
|
Printer-friendly Version
Email an Associate
